GH – Guardant Health, Inc.
Float Short %
7.62
Margin Of Safety %
Put/Call OI Ratio
1
EPS Next Q Diff
-0.05
EPS Last/This Y
1.75
EPS This/Next Y
0.37
Price
103.08
Target Price
131.52
Analyst Recom
1.52
Performance Q
7.88
Upside
-212.4%
Beta
1.66
Ticker: GH
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | GH | 114.83 | 0.80 | 0.32 | 16685 |
| 2026-01-26 | GH | 114.78 | 0.80 | 1.62 | 16757 |
| 2026-01-27 | GH | 114.51 | 0.81 | 0.15 | 16865 |
| 2026-01-28 | GH | 109.76 | 0.80 | 0.08 | 17047 |
| 2026-01-29 | GH | 110.44 | 0.72 | 0.31 | 18221 |
| 2026-01-30 | GH | 114.04 | 0.72 | 0.19 | 18337 |
| 2026-02-02 | GH | 114.96 | 0.70 | 1.92 | 18563 |
| 2026-02-03 | GH | 112.99 | 0.71 | 0.09 | 18632 |
| 2026-02-04 | GH | 106.18 | 0.71 | 13.32 | 18649 |
| 2026-02-05 | GH | 98.31 | 1.17 | 0.83 | 23348 |
| 2026-02-06 | GH | 101.85 | 1.16 | 6.67 | 23359 |
| 2026-02-09 | GH | 104.9 | 1.20 | 0.23 | 23871 |
| 2026-02-10 | GH | 105.13 | 1.20 | 0.97 | 23905 |
| 2026-02-11 | GH | 107.62 | 1.21 | 0.45 | 24042 |
| 2026-02-12 | GH | 102.72 | 1.20 | 0.65 | 24140 |
| 2026-02-13 | GH | 104.86 | 1.21 | 19.10 | 24126 |
| 2026-02-17 | GH | 107.05 | 1.16 | 4.79 | 23591 |
| 2026-02-18 | GH | 107.37 | 1.08 | 11.08 | 22854 |
| 2026-02-20 | GH | 103.29 | 1.00 | 0.70 | 23099 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | GH | 114.78 | 23.8 | 56.3 | -1.81 |
| 2026-01-26 | GH | 114.86 | 24.1 | 49.0 | -1.81 |
| 2026-01-27 | GH | 114.50 | 24.1 | 50.0 | -1.81 |
| 2026-01-28 | GH | 109.84 | 24.1 | 62.9 | -1.81 |
| 2026-01-29 | GH | 110.44 | 24.1 | 47.2 | -1.81 |
| 2026-01-30 | GH | 114.10 | 24.1 | 38.6 | -1.81 |
| 2026-02-02 | GH | 114.91 | 24.1 | 46.7 | -1.81 |
| 2026-02-03 | GH | 113.04 | 24.1 | 57.0 | -1.81 |
| 2026-02-04 | GH | 106.23 | 24.1 | 71.4 | -1.81 |
| 2026-02-05 | GH | 98.37 | 24.1 | 75.8 | -1.81 |
| 2026-02-06 | GH | 101.88 | 24.1 | 40.0 | -1.81 |
| 2026-02-09 | GH | 105.36 | 24.1 | 38.1 | -1.81 |
| 2026-02-10 | GH | 105.08 | 24.1 | 50.3 | -1.81 |
| 2026-02-11 | GH | 107.58 | 24.1 | 41.4 | -1.81 |
| 2026-02-12 | GH | 102.70 | 24.1 | 64.2 | -1.81 |
| 2026-02-13 | GH | 104.83 | 24.1 | 42.6 | -1.81 |
| 2026-02-17 | GH | 107.04 | 24.1 | 42.5 | -1.81 |
| 2026-02-18 | GH | 107.39 | 24.1 | 48.5 | -1.81 |
| 2026-02-19 | GH | 106.25 | 24.1 | - | -1.81 |
| 2026-02-20 | GH | 103.08 | 24.3 | - | -1.81 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | GH | -13.23 | 1.56 | 8.33 |
| 2026-01-26 | GH | -13.23 | 1.03 | 8.33 |
| 2026-01-27 | GH | -13.23 | 1.03 | 8.33 |
| 2026-01-28 | GH | -13.26 | 1.03 | 7.88 |
| 2026-01-29 | GH | -13.26 | 1.03 | 7.88 |
| 2026-01-30 | GH | -13.26 | 1.03 | 7.88 |
| 2026-02-02 | GH | -13.26 | 0.41 | 7.88 |
| 2026-02-03 | GH | -13.26 | 0.41 | 7.88 |
| 2026-02-04 | GH | -13.26 | 0.41 | 7.88 |
| 2026-02-05 | GH | -13.26 | 0.41 | 7.88 |
| 2026-02-06 | GH | -13.26 | 0.41 | 7.88 |
| 2026-02-09 | GH | -13.26 | 0.52 | 7.88 |
| 2026-02-10 | GH | -13.26 | 0.52 | 7.88 |
| 2026-02-11 | GH | -13.26 | 0.52 | 7.62 |
| 2026-02-12 | GH | -13.26 | 0.52 | 7.62 |
| 2026-02-13 | GH | -13.26 | 0.52 | 7.62 |
| 2026-02-17 | GH | -13.26 | 5.91 | 7.62 |
| 2026-02-18 | GH | -13.26 | 5.91 | 7.62 |
| 2026-02-19 | GH | -13.26 | 5.91 | 7.62 |
| 2026-02-20 | GH | -13.26 | 5.91 | 7.62 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.39
Avg. EPS Est. Current Quarter
-0.47
Avg. EPS Est. Next Quarter
-0.44
Insider Transactions
-13.26
Institutional Transactions
5.91
Beta
1.66
Average Sales Estimate Current Quarter
267
Average Sales Estimate Next Quarter
275
Fair Value
Quality Score
25
Growth Score
51
Sentiment Score
73
Actual DrawDown %
39.7
Max Drawdown 5-Year %
-90.6
Target Price
131.52
P/E
Forward P/E
PEG
P/S
13.58
P/B
P/Free Cash Flow
EPS
-3.31
Average EPS Est. Cur. Y
-1.81
EPS Next Y. (Est.)
-1.44
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-42.39
Relative Volume
2.5
Return on Equity vs Sector %
83.5
Return on Equity vs Industry %
101.5
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Guardant Health, Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees:
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Palo Alto, California.
stock quote shares GH – Guardant Health, Inc. Stock Price stock today
news today GH – Guardant Health, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GH – Guardant Health, Inc. yahoo finance google finance
stock history GH – Guardant Health, Inc. invest stock market
stock prices GH premarket after hours
ticker GH fair value insiders trading